05007(Millions of yen)100,000■ Net sales ■ Operating profit ● Ratio of operating profit to net sales86,90285,20980,00076,72217.060,00012.540,0009.720,00014,73110,6317,42420162017201896,75489,17188,95422.7201513.813.91021,94212,34712,333201920202021（％）25 (Fiscal year ended September 2021)Percentage of dermatologists who answered“No. 1 /High” in surveyCreated based on a Rep-i web survey for dermatologists in Japan (Aug. 2021) by INTAGE Healthcare Inc.Aug. 2021 survey: 544 respondents* Unauthorized reproduction prohibitedMessage from the President & CEOMaruho’s Sales Composition by Skin Disease Area (Prescription Drugs)Maruho Medical Representatives Ranked No. 1 Overall among Dermatologists in JapanDermatology96%During the fiscal year ended September 2021, our business performance remained solid with both net sales and profits marking record highs. Consolidated net sales increased 8.8% from the previous fiscal year, to 96,754 million yen, and net sales in our pharmaceutical business reached 87,724 million yen (up 8.5% from the previous fiscal year). In terms of profits, we recorded operating profit of 21,942 million yen (up 77.9%) and profit attributable to owners of parent of 14,902 million yen (up 135.9%), both marking a significant increase from the previous fiscal year. It was a meaningful year as our strategic measures and initiatives worked effectively and gave momentum to our efforts to achieve sustainable growth.With its unique know-how and expertise on topical drugs, Maruho contributes to the skin health of patients suffering from a variety of diseases, such as atopic dermatitis, acne, psoriasis, and infectious diseases. In addition to the high-quality products that we provide, information provision activities by our medical representatives (MRs) have also gained a high reputation and trust from dermatologists in Japan. Another strength is our positive alliances with various partners. We have established partnerships with major pharmaceutical companies based overseas and promoted licensing activities with pharmaceutical companies and research institutes both in Japan and overseas, thereby broadening the possibility of dermatological disease treatment. We have also expanded our business areas through collaboration and partnerships with our Group companies both inside and outside Japan, to provide appropriate solutions to diverse dermatological needs in a wider range of fields, such as diagnostic drugs, medical devices, and self-care. In particular, Maruho Hatsujyo Kogyo Co., Ltd., which started as a department within Maruho, still maintains close coordination with Maruho today. By utilizing its advanced precision processing technology, it is growing steadily and is engaged in a broad range of businesses, including springs, medical devices and components, and machinery.Business results for the fiscal year ended September 2021(October 2020 to September 2021)Maruho’s expertise and strengthsMarket Share (88.9 billion yen for the previous fiscal year)Copyright © 2021 IQVIA.Internal analysis based on IQVIA JPM Apr. 2020 - Mar. 2021* Unauthorized reproduction prohibited Topical drugs: Ointments, liquids, creams, lotions, and gels Net sales of the Maruho GroupNet sales / Operating profit /Ratio of operating profit to net salesNo. 1 Sales of Prescription Topical Drugs in JapanColoproctology, Internal Medicine, and Others 4%Skin Disease39%96%59.4%96.7billion yenNo. 1No. 1
元のページ ../index.html#9